Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits

Neuroscience

Volumn 29, Issue 2, 1989, Pages 339-346

  Beal, M F ^a   Mazurek, M F ^a   Ellison, D W ^a   Kowall, N W ^a   Solomon, P R ^b   Pendlebury, W W ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WILLIAMS COLLEGE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; CHOLINE ACETYLTRANSFERASE; MONOAMINE; NEUROPEPTIDE; NEUROTRANSMITTER;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN CORTEX; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; RABBIT; ANIMAL; ARTICLE; BRAIN; DRUG EFFECT; METABOLISM; NEUROFILAMENT; PATHOLOGY;

ALUMINUM; ALZHEIMER DISEASE; ANIMAL; BRAIN; NEUROFIBRILS; NEUROTRANSMITTERS; RABBITS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024478190     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(89)90061-4     Document Type: Article

References (78)

1. Vasoactive intestinal peptide is a physiological mediator of prolactin release in the rat
2. Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer's type dementia
3. Uber ein eigenartige erkrankung der hinnrinde
4. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia
5. Temporal patterns of somatostatin immunoreactivity in the cerebrospinal fluid of the rhesus monkey: effect of environmental lighting
6. A comparison of regional somatostatin and neuropeptide Y distribution in rat striatum and brain
7. Neuropeptides in neurological disease
8. Topographical dopamine and serotonin distribution and turnover in rat striatum
9. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease
10. Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex
11. An examination of neuropeptide Y postmortem stability in an animal model simulating human autopsy conditions
12. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease
13. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay
14. Fluorometric assay of proteins in the nanogram range
15. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia
16. Aluminosilicates and senile plaque formation in Alzheimer's disease
17. The regional distribution of somatostatin, substance P and neurotensin in human brain
18. Aluminum induced neurofibrillary degeneration, brain electrical activity and alterations in acquisition and retention
19. Cortical substances P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type
20. Nucleus Raphe Dorsalis in Dementia of the Alzheimer Type
21. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia
22. Selective loss of central cholinergic neurons in Alzheimer's disease
23. Decreased somatostatin immuno-reactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type
24. Localization of glutaminase and aspartate amino transferase-like immunoreactivity in neurons of cerebral cortex
25. A postmortem study of amino acid neurotransmitters in Alzheimer's disease
26. AMINO ACID NEUROTRANSMITTER ABNORMALITIES IN HUNTINGTON'S DISEASE AND THE QUINOLINIC ACID ANIMAL MODEL OF HUNTINGTON'S DISEASE
27. Neuropeptides in Alzheimer type dementia
28. Radiochemical microassays for the determination of choline acetyltransferase and acetyl-cholinesterase activities
29. Comparative toxicity of intracerebroventricular and subcutaneous aluminum in the rabbit
30. Neurochemical studies of early onset Alzheimer's disease, possible influence on treatment
31. Nerve cell loss in the progressive encephalopathy induced by aluminum powder. A morphologic and semiquantitative study of the Purkinje cells
32. Biochemical changes in dementia disorders of Alzheimer type
33. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology.
34. Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex
35. Central cholinergic activity in aluminum-induced neurofibrillary degeneration
36. The peptide containing neurons of the primate cerebral cortex
37. Effect of aluminum upon conditioned avoidance response acquisition in the absence of neurofibrillary degeneration
38. Experimental production of neurofibrillary degeneration. I. Light microscopic observation
39. Cholinergic Function in Lumbar Aluminum Myelopathy
40. Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer disease
41. Somatostatin, neuropeptide Y, NADPH-diaphorase neurons do not contain neurofibrillary tangles in AD cortex
42. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: a quantitative study of visual and auditory cortices
43. Changes in the monoamine containing neurons of the human central nervous system in senile dementia
44. Neuropeptides in Alzheimer's disease: clinical implications
45. Regional brain concentrations of neurotensin, thyrotropin releasing hormone and somatostatin in alzheimer's disease
46. Taurine in the hippocompal formation of the senqalese baboon,Papio papio: an immunocytochemical study with an antiserum against conjugated taurine
47. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease
48. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons
49. Neurochemical activities in human temporal lobe related to aging with Alzheimer-type changes
50. Neuropeptides in Alzheimer's disease, depression and schizophrenia: a postmortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex
51. Necropsy evidence of central cholinergic deficits in senile dementia
52. Correlation of cholinergic abnormalities with senile plaques and mental test scores on senile dementia
53. Amino acid abnormalities in epileptogenic foci
54. Neurobehavioural development following aluminum administration in infant rabbits
55. Neurofibrillary degeneration, dendritic dying back, and learning-memory deficits after aluminum administrations for brain aging
56. Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer's disease
57. Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide
58. A postmortem study of the cholinergic and GABA systems in senile dementia
59. Neurochemical characteristics of early and late onset types of Alzheimer's disease
60. Normal cortical concentration of cholecystokinin-like immunoreactivity with reduced choline acetyltransferase activity in senile dementia of Alzheimer type
61. Regional distribution of amino acids in postmortem brains of presenile and senile dementia of Alzheimer type
62. The rabbit diencephalon in stereotaxic coordinates
63. Biochemical studies on rabbits with aluminum induced neurofilament accumulations
64. Disruption of aquisition and retention of the classically conditioned eyeblink response in rabbits with aluminum induced neurofibrillary tangles
65. Aberrant neurofilament phosphorytation in Alzheimer disease
66. High affinity uptake of GABA and glycine by rabbits with aluminum-induced neurofibrillary changes
67. Taurine in hipocompus: localization and postsynaptic action
68. Experimental production of neurofibrillary degeneration. II. Electronmicroscopy, phosphatase histochemistry and electron probe analysis
69. Cell loss in the locus coeruleus in senile dementia of Alzheimer type
70. Immunocytochemical studies of neurofilament antigens in the neurofibrillary pathology induced by aluminum
71. Intranuclear aluminum accumulation in chronic animals with experimental neurofibrillary changes
72. Nucleus raphe dorsalis in Alzheimer's disease: neurofibrillary tangles and loss of large neurons
73. Neurofibrillary degeneration induced in the rabbit by aluminum chloride: aluminum neurofibrillary tangles
74. Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease
75. Cholinergic enzymes in neurofibrillary degeneration produced by aluminum
76. Immunohistochemistry of taurine and GABA in serial brain sections of the rat
77. Topography and dynamics of neurofibrillar degeneration in aluminum encephalopathy
78. Aluminum chloride induced neurofibrillary changes in the developing rabbit: a chronic animal model